DK2453890T3 - Sammensætninger omfattende en kolinesterase-inhibitor til behandling af kognitive lidelser - Google Patents
Sammensætninger omfattende en kolinesterase-inhibitor til behandling af kognitive lidelser Download PDFInfo
- Publication number
- DK2453890T3 DK2453890T3 DK10735143.9T DK10735143T DK2453890T3 DK 2453890 T3 DK2453890 T3 DK 2453890T3 DK 10735143 T DK10735143 T DK 10735143T DK 2453890 T3 DK2453890 T3 DK 2453890T3
- Authority
- DK
- Denmark
- Prior art keywords
- colinesterase
- inhibitor
- treatment
- compositions including
- cognitive disorders
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22642509P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042308 WO2011009061A1 (en) | 2009-07-17 | 2010-07-16 | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2453890T3 true DK2453890T3 (da) | 2020-08-17 |
Family
ID=42990151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10735143.9T DK2453890T3 (da) | 2009-07-17 | 2010-07-16 | Sammensætninger omfattende en kolinesterase-inhibitor til behandling af kognitive lidelser |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110015179A1 (enExample) |
| EP (1) | EP2453890B1 (enExample) |
| JP (1) | JP2012533566A (enExample) |
| KR (1) | KR101757003B1 (enExample) |
| CN (1) | CN102497861A (enExample) |
| AU (1) | AU2010273977A1 (enExample) |
| BR (1) | BR112012001047A2 (enExample) |
| CA (1) | CA2768356A1 (enExample) |
| DK (1) | DK2453890T3 (enExample) |
| ES (1) | ES2809298T3 (enExample) |
| IN (1) | IN2012DN01209A (enExample) |
| PT (1) | PT2453890T (enExample) |
| RU (2) | RU2016151986A (enExample) |
| WO (1) | WO2011009061A1 (enExample) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| WO2005072713A2 (en) | 2004-01-27 | 2005-08-11 | The Feinstein Institute For Medical Research | Cholinesterase inhibitors for treating inflammation |
| US20070212253A1 (en) * | 2004-12-21 | 2007-09-13 | Elrod Scott A | Descenting systems and methods |
| DK1841423T3 (da) * | 2005-01-26 | 2010-06-07 | Allergan Inc | Anvendelse af 1-benzyl-1-hydroxy-2,3-diamino-propylaminer, 3-benzyl-3-hydroxy-2-aminopropionsyre-amider og beslægtede forbindelser som analgetika |
| WO2007012154A1 (en) * | 2005-07-27 | 2007-02-01 | Carlos Henrique Horta Lima | Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties. |
| US7678363B2 (en) * | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2008109285A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
| US20100190792A1 (en) * | 2007-03-06 | 2010-07-29 | Allergan, Inc | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| CA2680324A1 (en) * | 2007-03-06 | 2008-09-12 | John E. Donello | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| CN101778628B (zh) * | 2007-07-17 | 2013-02-06 | 阿勒根公司 | 治疗焦虑的方法 |
-
2010
- 2010-07-16 US US12/838,019 patent/US20110015179A1/en not_active Abandoned
- 2010-07-16 EP EP10735143.9A patent/EP2453890B1/en active Active
- 2010-07-16 BR BR112012001047A patent/BR112012001047A2/pt not_active IP Right Cessation
- 2010-07-16 IN IN1209DEN2012 patent/IN2012DN01209A/en unknown
- 2010-07-16 RU RU2016151986A patent/RU2016151986A/ru not_active Application Discontinuation
- 2010-07-16 RU RU2012103401A patent/RU2607946C2/ru not_active Application Discontinuation
- 2010-07-16 KR KR1020127003979A patent/KR101757003B1/ko active Active
- 2010-07-16 ES ES10735143T patent/ES2809298T3/es active Active
- 2010-07-16 CN CN201080041187XA patent/CN102497861A/zh active Pending
- 2010-07-16 AU AU2010273977A patent/AU2010273977A1/en not_active Abandoned
- 2010-07-16 WO PCT/US2010/042308 patent/WO2011009061A1/en not_active Ceased
- 2010-07-16 PT PT107351439T patent/PT2453890T/pt unknown
- 2010-07-16 CA CA2768356A patent/CA2768356A1/en not_active Abandoned
- 2010-07-16 JP JP2012520814A patent/JP2012533566A/ja active Pending
- 2010-07-16 DK DK10735143.9T patent/DK2453890T3/da active
-
2012
- 2012-10-11 US US13/649,404 patent/US9492543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2607946C2 (ru) | 2017-01-11 |
| US9492543B2 (en) | 2016-11-15 |
| WO2011009061A1 (en) | 2011-01-20 |
| RU2016151986A (ru) | 2018-12-19 |
| US20110015179A1 (en) | 2011-01-20 |
| ES2809298T3 (es) | 2021-03-03 |
| EP2453890B1 (en) | 2020-05-27 |
| IN2012DN01209A (enExample) | 2015-04-10 |
| AU2010273977A1 (en) | 2012-02-02 |
| US20130040938A1 (en) | 2013-02-14 |
| JP2012533566A (ja) | 2012-12-27 |
| CN102497861A (zh) | 2012-06-13 |
| RU2012103401A (ru) | 2013-08-27 |
| BR112012001047A2 (pt) | 2019-09-24 |
| PT2453890T (pt) | 2020-08-25 |
| KR101757003B1 (ko) | 2017-07-11 |
| EP2453890A1 (en) | 2012-05-23 |
| KR20120090029A (ko) | 2012-08-16 |
| CA2768356A1 (en) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| PL3354276T3 (pl) | Kompozycje do leczenia zapalenia przewodu pokarmowego | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| DOP2012000114A (es) | Inhibidor bromodominio de benzodiazepina | |
| PT2398774T (pt) | Processos para a preparação de inibidores jak e compostos intermediários relacionados | |
| DK2558105T3 (da) | Bardoxolonmethyl til behandling af fedme | |
| DK2114886T3 (da) | Fremgangsmåde til fremstilling af visse substituerede sulfiliminer | |
| DK2509684T3 (da) | Anordning til behandling af rhinitis ved biostimulerende belysning | |
| DK2346321T4 (da) | Sammensætning til forbedring af effektiviteten af herbicider | |
| DK3284820T3 (da) | Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger | |
| DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| DK2451796T3 (da) | Tofaanaloger til behandling af dermatologiske lidelser eller tilstande | |
| DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
| DK2209900T3 (da) | Anvendelse af bakterier til fremstillingen af bioenergi | |
| DK2526425T3 (da) | Fremgangsmåde til diagnosticering af endometriel receptivitet | |
| DK3305317T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| PL2437742T3 (pl) | Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń | |
| PL2493466T3 (pl) | Nowe przeciwguzowe zastosowanie kabazytakselu | |
| SMT201500281B (it) | Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari | |
| HUE040085T2 (hu) | PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére | |
| EP2413941A4 (en) | Renin Inhibitors |